Vascular Biogenics ROA 2024

Vascular Biogenics Aktienanalyse

What does Vascular Biogenics do?

Vascular Biogenics Ltd (VBL) is a biopharmaceutical company that was founded in 2000. The company is headquartered in Modi'in, Israel and is listed on the NASDAQ under the ticker symbol "VBLT". The history of VBL dates back to the discovery of a protein called Vascular Endothelial Growth Factor-B (VEGF-B) by the company's founder, Professor Moshe Deutsch. VEGF-B is considered a key regulator in blood vessel formation and diseases such as cancer, macular degeneration, and arteriosclerosis. VBL's business model is based on the development and commercialization of novel therapies based on the use of VEGF-B. The company focuses on the development of cancer therapies as well as the treatment of eye diseases and inflammatory diseases. VBL is divided into three divisions: 1. Oncology: In this division, VBL is developing a novel therapy for the treatment of cancer based on a encapsulated version of VEGF-B. This therapy aims to slow tumor growth and activate the patient's immune system to fight the tumor. VBL currently has several ongoing clinical trials that show promising results. 2. Ophthalmology: In this division, VBL is investigating the use of VEGF-B in the treatment of macular degeneration, an eye disease that can lead to vision loss. The company has developed a drug called "VB-421" that has been successfully tested in clinical trials. 3. Inflammatory diseases: VBL is also working on the development of therapies for inflammatory diseases such as rheumatism and colitis. The company also uses the VEGF-B active ingredient for this purpose. In recent years, VBL has already brought several drugs to the market and is continuously working on the development of new therapies. The company collaborates closely with various universities and research institutions. Overall, VBL has achieved promising results in research in recent years and has conducted numerous successful clinical trials. The company focuses on the development of therapies for severe diseases for which there is currently no effective treatment. VBL aims to improve the lives of patients worldwide and make great progress in medicine. Vascular Biogenics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Vascular Biogenics's Return on Assets (ROA)

Vascular Biogenics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Vascular Biogenics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Vascular Biogenics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Vascular Biogenics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Vascular Biogenics Stock

What is the Return on Assets (ROA) of Vascular Biogenics this year?

The Return on Assets (ROA) of Vascular Biogenics is -1.09 undefined this year.

What was the ROA of Vascular Biogenics compared to the previous year?

The ROA of Vascular Biogenics has increased by 135.39% compared to the previous year.

What consequences do high ROA have for investors of Vascular Biogenics?

A high ROA is advantageous for investors of Vascular Biogenics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Vascular Biogenics?

A low ROA can be unfavorable for investors of Vascular Biogenics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Vascular Biogenics affect the company?

An increase in ROA of Vascular Biogenics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Vascular Biogenics impact the company?

A reduction in the ROA of Vascular Biogenics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Vascular Biogenics?

Some factors that can influence the ROA of Vascular Biogenics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Vascular Biogenics important for investors?

The ROA of Vascular Biogenics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Vascular Biogenics take to improve ROA?

To improve ROA, Vascular Biogenics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Vascular Biogenics pay?

Over the past 12 months, Vascular Biogenics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vascular Biogenics is expected to pay a dividend of 0 USD.

What is the dividend yield of Vascular Biogenics?

The current dividend yield of Vascular Biogenics is .

When does Vascular Biogenics pay dividends?

Vascular Biogenics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Vascular Biogenics?

Vascular Biogenics paid dividends every year for the past 0 years.

What is the dividend of Vascular Biogenics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Vascular Biogenics located?

Vascular Biogenics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vascular Biogenics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vascular Biogenics from 6/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/26/2024.

When did Vascular Biogenics pay the last dividend?

The last dividend was paid out on 6/26/2024.

What was the dividend of Vascular Biogenics in the year 2023?

In the year 2023, Vascular Biogenics distributed 0 USD as dividends.

In which currency does Vascular Biogenics pay out the dividend?

The dividends of Vascular Biogenics are distributed in USD.